Generali Investments Towarzystwo Funduszy Inwestycyjnych Boosts Stake in Boston Scientific Corporation $BSX

Generali Investments Towarzystwo Funduszy Inwestycyjnych lifted its holdings in Boston Scientific Corporation (NYSE:BSX) by 120.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 22,000 shares of the medical equipment provider’s stock after acquiring an additional 12,000 shares during the quarter. Boston Scientific accounts for 1.0% of Generali Investments Towarzystwo Funduszy Inwestycyjnych’s holdings, making the stock its 28th biggest position. Generali Investments Towarzystwo Funduszy Inwestycyjnych’s holdings in Boston Scientific were worth $2,098,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in BSX. Parnassus Investments LLC increased its stake in shares of Boston Scientific by 42,978.9% in the third quarter. Parnassus Investments LLC now owns 6,884,440 shares of the medical equipment provider’s stock worth $672,128,000 after acquiring an additional 6,868,459 shares during the period. Egerton Capital UK LLP raised its stake in shares of Boston Scientific by 223.7% during the 3rd quarter. Egerton Capital UK LLP now owns 5,312,504 shares of the medical equipment provider’s stock worth $518,660,000 after buying an additional 3,671,548 shares during the period. Jennison Associates LLC lifted its position in shares of Boston Scientific by 133.5% during the 3rd quarter. Jennison Associates LLC now owns 4,938,746 shares of the medical equipment provider’s stock valued at $482,170,000 after buying an additional 2,823,744 shares in the last quarter. Marshall Wace LLP grew its position in shares of Boston Scientific by 30.7% in the third quarter. Marshall Wace LLP now owns 9,799,040 shares of the medical equipment provider’s stock valued at $956,680,000 after purchasing an additional 2,301,383 shares during the period. Finally, Credit Agricole S A acquired a new stake in shares of Boston Scientific in the third quarter valued at about $204,812,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Analyst support remains: Truist trimmed its price target to $90 but kept a Buy rating, and Citi has reiterated a Buy stance (prior target reductions noted). The sustained Buy ratings support upside sentiment despite lower targets. Truist price target note Citi reiteration
• Positive Sentiment: Earnings expectations are constructive: recent pieces (Zacks, Yahoo) highlight that BSX appears positioned for an earnings beat in the upcoming report, citing favorable revenue/expense dynamics and consensus-beating potential—this can support near-term upside if results meet or beat expectations. Zacks earnings preview Yahoo earnings preview
• Neutral Sentiment: Competitive landscape update: AIP’s announced $1.27B take-private of Avanos (a competitor in some product areas) could change competitive dynamics in adjacent markets, but direct impact on BSX revenue/margins is unclear at this stage. MedTechDive Avanos takeover
• Neutral Sentiment: Market commentary: Overnight/early coverage noted BSX outperformed the broader market in recent sessions, reflecting mixed investor responses to the above factors. Zacks market note
• Negative Sentiment: Legal risk rising: Multiple law firms have filed or announced investor alerts about securities-class-action claims alleging that BSX (and some officers) misrepresented U.S. electrophysiology procedure growth; several firms are soliciting lead-plaintiff motions with a May 4, 2026 deadline. This cluster of lawsuits increases litigation risk and could pressure the stock if damages or disclosures follow. Rosen class action notice Levi & Korsinsky alert

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on BSX shares. Oppenheimer lowered their price target on shares of Boston Scientific from $125.00 to $100.00 and set an “outperform” rating on the stock in a research report on Friday, January 16th. Robert W. Baird lowered their price target on shares of Boston Scientific from $118.00 to $101.00 and set an “outperform” rating on the stock in a research report on Thursday, February 5th. Needham & Company LLC restated a “buy” rating and set a $97.00 price target on shares of Boston Scientific in a research report on Monday, March 30th. Morgan Stanley lowered their price target on shares of Boston Scientific from $130.00 to $118.00 and set an “overweight” rating on the stock in a research report on Thursday, February 5th. Finally, JPMorgan Chase & Co. lowered their price target on shares of Boston Scientific from $135.00 to $100.00 and set an “overweight” rating on the stock in a research report on Thursday, February 5th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, Boston Scientific presently has a consensus rating of “Moderate Buy” and an average price target of $102.82.

Insiders Place Their Bets

In other news, CEO Michael F. Mahoney sold 160,901 shares of the business’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the sale, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. The trade was a 10.23% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.34% of the stock is owned by insiders.

Boston Scientific Stock Performance

NYSE:BSX opened at $64.61 on Thursday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08. The firm has a market capitalization of $96.02 billion, a price-to-earnings ratio of 33.30, a PEG ratio of 0.99 and a beta of 0.78. The company’s 50-day moving average is $70.12 and its two-hundred day moving average is $87.35. Boston Scientific Corporation has a 1-year low of $60.59 and a 1-year high of $109.50.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.78 by $0.02. The company had revenue of $5.29 billion for the quarter, compared to analyst estimates of $5.29 billion. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. Boston Scientific’s revenue was up 15.9% on a year-over-year basis. During the same period in the previous year, the business posted $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.